Brain Advance Access originally published online on July 1, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 127, No. 8, 1868-1877,
August 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh210
Homozygosity for CCTG mutation in myotonic dystrophy type 2
1 Friedrich Baur Institute, Department of Neurology, Ludwig Maximilians University, Munich, 2 Institute of Human Genetics and 3 Department of Neurology, Julius Maximilians University, Würzburg, Germany
Correspondence to: Dr Benedikt G. H. Schoser, Friedrich Baur Institute, Department of Neurology, Ludwig Maximilians University, Ziemssenstr. 1a, D-80336 Munich, Germany E-mail: bschoser{at}fbs.med.uni-muenchen.de
Myotonic dystrophy type 2 (DM2) is caused by a dominantly transmitted CCTG repeat expansion in intron 1 of the zinc finger protein 9 (ZNF9) gene on chromosome 3q. DM2 patients with two mutant alleles have not been reported so far. In one large consanguineous family from Afghanistan, we found three homozygotes for the DM2 mutation. The oldest patient was clinically more severely affected, compared with the two younger homozygotes, but for the clinical course of symptoms all three homozygotes were within the range expected for heterozygotes. Further investigations, such as mutation repeat length, muscle histology, anti-muscleblind-like 1 stainings or brain imaging studies, at least at short-term observation, showed no differences between heterozygotes and homozygotes. Twenty of 24 children, aged 221 years, were available for clinical examination. None of these children have signs or symptoms of disease until the age of 18 years. Homozygosity for the DM2 expansion does not seem to alter the disease phenotype as compared with the heterozygous state.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
Y. Yuan, S. A. Compton, K. Sobczak, M. G. Stenberg, C. A. Thornton, J. D. Griffith, and M. S. Swanson Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs Nucleic Acids Res., August 15, 2007; (2007) gkm601v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S G Meuth, C Kleinschnitz, M Frank, C Wessig, M Bendszus, W Kress, and H Wiendl Why a positive genetic test for myotonic dystrophy type I does not always imply the right diagnosis. J. Neurol. Neurosurg. Psychiatry, December 1, 2006; 77(12): 1381 - 1382. [Full Text] [PDF] |
||||
![]() |
R. J. Osborne and C. A. Thornton RNA-dominant diseases Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R162 - R169. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Margolis, B. G. Schoser, M. L. Moseley, J. W. Day, and L. P.W. Ranum DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression Hum. Mol. Genet., June 1, 2006; 15(11): 1808 - 1815. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M Lovering, N. C Porter, and R. J Bloch The Muscular Dystrophies: From Genes to Therapies Physical Therapy, December 1, 2005; 85(12): 1372 - 1388. [Abstract] [Full Text] [PDF] |
||||



